Tags

Type your tag names separated by a space and hit enter

Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis.
Spine (Phila Pa 1976). 2009 Mar 15; 34(6):551-5.S

Abstract

STUDY DESIGN

Myelopathy symptoms were prospectively studied in patients with cervical spinal canal stenosis (CSCS), using objective grading systems and stabilometry, to examine the effect of administration of prostaglandin E1 derivative limaprost alfadex (limaprost).

OBJECTIVE

Myelopathy scores/grades and stabilometry parameters were evaluated before, and 1 and 3 months after starting the limaprost treatment.

SUMMARY AND BACKGROUND DATA

Limaprost is a potent vasodilator and antiplatelet agent and has been used to treat the symptoms of lumbar spinal canal stenosis. The action presumably involves increased blood flow in the compressed cauda equina. Limaprost can also increase blood flow in the compressed spinal cord, but effects on myelopathy symptoms in patients with CSCS have not been established.

METHODS

This study examined 21 patients with mild spondylotic CSCS based on neurologic findings and compression of the cervical spinal cord on magnetic resonance imaging. Japanese Orthopedic Association score, grip and release test, and finger escape sign were measured, and stabilometry was performed by independent examiners, before, and 1 and 3 months after starting the oral limaprost treatment.

RESULTS

Most patients experienced amelioration of the symptoms at 1 month after starting the treatment. Mean Japanese Orthopedic Association score and grip and release count were significantly improved and finger escape sign grade was higher in some patients. Stabilometry area with eyes closed and Romberg rate were also significantly improved. These improvements were maintained at 3 months.

CONCLUSION

The efficacy of oral limaprost administration for patients with CSCS was confirmed by objective scoring and quantitative data.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Sugawara T
Department of Neurosurgery, Akita University School of Medicine, Akita, Japan. taku@nsg.med.akitau.ac.jp
Hirano Y
No affiliation info available
Higashiyama N
No affiliation info available
Mizoi K
No affiliation info available

MeSH

Administration, OralAgedAged, 80 and overAlprostadilCervical VertebraeDizzinessFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMotor SkillsPlatelet Aggregation InhibitorsPostural BalanceProspective StudiesSpinal StenosisSpondylosisTreatment OutcomeVasodilator Agents

Pub Type(s)

Case Reports
Clinical Trial
Journal Article

Language

eng

PubMed ID

19282734

Citation

Sugawara, Taku, et al. "Limaprost Alfadex Improves Myelopathy Symptoms in Patients With Cervical Spinal Canal Stenosis." Spine, vol. 34, no. 6, 2009, pp. 551-5.
Sugawara T, Hirano Y, Higashiyama N, et al. Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis. Spine (Phila Pa 1976). 2009;34(6):551-5.
Sugawara, T., Hirano, Y., Higashiyama, N., & Mizoi, K. (2009). Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis. Spine, 34(6), 551-5. https://doi.org/10.1097/BRS.0b013e31819a84ec
Sugawara T, et al. Limaprost Alfadex Improves Myelopathy Symptoms in Patients With Cervical Spinal Canal Stenosis. Spine (Phila Pa 1976). 2009 Mar 15;34(6):551-5. PubMed PMID: 19282734.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis. AU - Sugawara,Taku, AU - Hirano,Yoshitaka, AU - Higashiyama,Naoki, AU - Mizoi,Kazuo, PY - 2009/3/14/entrez PY - 2009/3/14/pubmed PY - 2009/5/12/medline SP - 551 EP - 5 JF - Spine JO - Spine (Phila Pa 1976) VL - 34 IS - 6 N2 - STUDY DESIGN: Myelopathy symptoms were prospectively studied in patients with cervical spinal canal stenosis (CSCS), using objective grading systems and stabilometry, to examine the effect of administration of prostaglandin E1 derivative limaprost alfadex (limaprost). OBJECTIVE: Myelopathy scores/grades and stabilometry parameters were evaluated before, and 1 and 3 months after starting the limaprost treatment. SUMMARY AND BACKGROUND DATA: Limaprost is a potent vasodilator and antiplatelet agent and has been used to treat the symptoms of lumbar spinal canal stenosis. The action presumably involves increased blood flow in the compressed cauda equina. Limaprost can also increase blood flow in the compressed spinal cord, but effects on myelopathy symptoms in patients with CSCS have not been established. METHODS: This study examined 21 patients with mild spondylotic CSCS based on neurologic findings and compression of the cervical spinal cord on magnetic resonance imaging. Japanese Orthopedic Association score, grip and release test, and finger escape sign were measured, and stabilometry was performed by independent examiners, before, and 1 and 3 months after starting the oral limaprost treatment. RESULTS: Most patients experienced amelioration of the symptoms at 1 month after starting the treatment. Mean Japanese Orthopedic Association score and grip and release count were significantly improved and finger escape sign grade was higher in some patients. Stabilometry area with eyes closed and Romberg rate were also significantly improved. These improvements were maintained at 3 months. CONCLUSION: The efficacy of oral limaprost administration for patients with CSCS was confirmed by objective scoring and quantitative data. SN - 1528-1159 UR - https://www.unboundmedicine.com/medline/citation/19282734/Limaprost_alfadex_improves_myelopathy_symptoms_in_patients_with_cervical_spinal_canal_stenosis_ DB - PRIME DP - Unbound Medicine ER -